Through a comprehensive analysis of the limited literature, we believe that PDE-5 inhibitors can be safely used in patients with mild to moderate hepatic impairment, and due to the limited information on the clinical safety of this drug in patients with severe hepatic insufficiency, a lower starting dose of PDE-5 inhibitors should be considered. The gene discussed is PDE5A; the disease is Hepatic failure.